Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
VRNA | US
0.40
2.55%
Healthcare
Biotechnology
31/03/2024
05/07/2024
16.11
15.67
16.28
15.56
Verona Pharma plc a clinical stage biopharmaceutical company focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease asthma and cystic fibrosis. It is developing ensifentrine in three formulations including nebulizer dry powder inhaler and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London the United Kingdom.
View LessLow Market Beta (-0.4 to 0.8)
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
High Short-term Volatility
Smallcap (300M - 2B USD)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
68.2%1 month
79.6%3 months
57.2%6 months
53.7%-
-
5.17
0.23
0.18
-20.88
2.53K
-
-72.41M
1.31B
1.31B
-
-
-
-
-25.28
7.78
9.94
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
Range10D
2.14
Range1M
5.21
Range3M
5.86
Rel. volume
0.72
Price X volume
20.22M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 14.78 | 1.42B | 1.72% | n/a | 46.87% |
MannKind Corporation | MNKD | Biotechnology | 5.13 | 1.40B | 1.99% | 130.50 | -162.73% |
Bicycle Therapeutics Limited | BCYC | Biotechnology | 20.21 | 1.39B | 3.22% | n/a | 12.31% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 19.36 | 1.37B | 1.36% | 143.62 | 2.81% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 34.87 | 1.36B | 9.28% | n/a | 1.27% |
Belite Bio Inc | BLTE | Biotechnology | 45.5 | 1.36B | -0.55% | n/a | 0.00% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 6.52 | 1.35B | 1.72% | n/a | -173.65% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 61.44 | 1.29B | 1.02% | 39.55 | 68.66% |
Arcus Biosciences Inc | RCUS | Biotechnology | 14.12 | 1.28B | -1.67% | n/a | 1.56% |
Ardelyx Inc | ARDX | Biotechnology | 5.29 | 1.24B | -0.56% | n/a | 69.54% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.45 | 1.31B | -0.37% | n/a | 20.15% |
REV Group Inc | REVG | Recreational Vehicles | 24.74 | 1.28B | -2.06% | 5.86 | 66.74% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.36 | 1.14B | 1.60% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.73 | 799.13M | -2.42% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 32.65 | 667.35M | -2.74% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.25 | 552.16M | -0.75% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.48 | 428.47M | -2.40% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 25.77 | 412.92M | -1.68% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.74 | 369.15M | -2.49% | 14.12 | 86.68% |
Marine Products Corporation | MPX | Recreational Vehicles | 9.36 | 324.63M | -2.40% | 10.10 | 0.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -20.88 | -2.43 | Cheaper |
Ent. to Revenue | 2,531.50 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 5.17 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 57.16 | 76.52 | Lower Risk |
Debt to Equity | 0.23 | 0.51 | Cheaper |
Debt to Assets | 0.18 | 0.24 | Cheaper |
Market Cap | 1.31B | 3.77B | Emerging |